Clindamycin

is prescribed to treat:

• Bacterial infections, especially skin and dental infections • Various related conditions in the antibiotics category • Associated symptoms and complications

It is an important medication that helps manage these conditions effectively.

Clindamycin (Cleocin) is a lincosamide antibiotic used for skin and soft-tissue infection including MRSA, dental and oral infections, anaerobic infections, and topically for acne. It has a valuable spectrum and a specific, well-earned reputation for causing C. difficile infection.

Mechanism of Action

Clindamycin binds the 50S ribosomal subunit, blocking peptide bond formation and halting protein synthesis. It is generally bacteriostatic, though bactericidal against some organisms at higher concentrations.

Its spectrum covers Gram-positive cocci including many strains of community-acquired MRSA, and anaerobes including Bacteroides and Peptostreptococcus. That combination — staphylococci, streptococci, and anaerobes in one oral agent — is why it suits dental infection, aspiration pneumonia, and deep soft-tissue infection.

Clindamycin has one property beyond simple killing that matters in severe disease: it suppresses bacterial toxin production by inhibiting protein synthesis. In necrotising fasciitis and streptococcal toxic shock syndrome it is added to a beta-lactam specifically for this reason, since the toxins drive much of the harm and a cell-wall agent does nothing to stop their production.

It penetrates bone and abscess cavities well, which supports its use in osteomyelitis and deep infection.

Inducible resistance is a practical issue in staphylococci. Some isolates test susceptible to clindamycin but carry a gene that can be switched on during treatment, producing failure partway through a course. The D-test detects this, and it should be requested when clindamycin is being considered for a staphylococcal infection.

The C. difficile Problem

Clindamycin has the strongest association with C. difficile infection of any commonly used antibiotic, and this shapes every decision to prescribe it.

The mechanism is straightforward: clindamycin's broad anaerobic activity devastates the normal colonic flora that ordinarily suppress C. difficile, allowing it to proliferate and produce toxin. The disruption is more complete and more prolonged than with narrower agents.

Risk persists for weeks after a course ends, so diarrhoea developing a month after treatment can still be attributable. It is not dose-dependent in any reassuring way — even short courses and topical use with systemic absorption have been implicated, though the risk from topical acne preparations is very low.

The practical consequence is that clindamycin should be used where its spectrum is genuinely needed rather than as a general-purpose alternative. For non-purulent cellulitis where streptococci predominate, cephalexin is preferred. For MRSA skin infection, doxycycline and trimethoprim-sulfamethoxazole carry lower C. difficile risk.

Patients should be told explicitly to report watery diarrhoea during or after the course rather than treating it with an antimotility agent such as loperamide, which is harmful in C. difficile. The CDC C. difficile resource covers recognition and treatment, and the antibiotic resistance article covers stewardship.

Clinical Use

Clindamycin is appropriate for dental and odontogenic infection, particularly in penicillin allergy; for MRSA skin infection where a D-test supports it; for anaerobic and mixed infections; and as an adjunct in toxin-mediated disease.

For endocarditis prophylaxis in the small group who still require it, clindamycin was long the standard alternative in penicillin allergy, though guidance has shifted toward other agents given the C. difficile risk.

Topical clindamycin is widely used in acne, usually combined with benzoyl peroxide — the combination matters, because benzoyl peroxide substantially reduces the emergence of resistant Cutibacterium acnes. Topical clindamycin alone for prolonged periods drives resistance and is discouraged. Our dermatologic team manages acne that is not responding.

Oesophageal irritation occurs with capsules, so they should be taken with a full glass of water and the patient should stay upright afterwards.

Monitoring and Follow-Up

Short courses in healthy patients require no laboratory monitoring. Prolonged therapy, as in osteomyelitis, warrants periodic blood counts and liver enzymes.

The critical clinical monitoring is for diarrhoea, and patients need to understand that this is not simply an inconvenient side effect. Watery diarrhoea, particularly with abdominal cramping or fever, warrants testing rather than watchful waiting.

Clinical response should be reassessed at 48 to 72 hours. Failure to improve raises inducible resistance in staphylococcal infection, an undrained abscess, or a wrong diagnosis. The MedlinePlus clindamycin entry covers prescribing detail.

Dosing frequency is worth getting right, because clindamycin's short half-life means it is dosed three or four times daily and adherence falls measurably with each additional daily dose. A patient taking it twice a day because four is impractical is under-treating without realising it. Where the schedule is genuinely unworkable, a different agent is a better answer than one the patient cannot follow.

Topical and vaginal preparations are a separate matter. Vaginal clindamycin cream treats bacterial vaginosis with minimal systemic absorption, and topical acne preparations deliver very little systemically — the C. difficile concern that dominates oral use does not translate to them in any practical sense.

Special Populations

In older adults, C. difficile risk is substantially higher and the consequences more severe, which argues for an alternative wherever one exists.

In pregnancy, clindamycin is used when indicated and has a reasonable safety record, including for bacterial vaginosis. It is compatible with breastfeeding, though infant gastrointestinal effects should be watched for.

In hepatic impairment, dose reduction may be warranted since clindamycin is hepatically metabolised; kidney impairment generally requires no adjustment. It is contraindicated in prior clindamycin-associated colitis. Patients with inflammatory bowel disease are at higher risk of severe colitis.

A penicillin allergy is a common reason clindamycin is chosen, but that label deserves scrutiny first — most reported penicillin allergies are not genuine, and confirming that often restores access to a safer, narrower antibiotic.

When to Contact Your Doctor

Report watery diarrhoea, abdominal cramping, or fever during treatment or in the weeks afterwards — do not take an antidiarrhoeal, which makes C. difficile worse. Severe abdominal pain with distension needs urgent assessment.

Report painful or difficult swallowing, which suggests oesophageal irritation from a capsule. Report any rash, particularly blistering or peeling or with fever.

Report failure to improve within two to three days. If you were prescribed clindamycin because of a penicillin allergy, it is worth asking whether that allergy has ever been properly assessed.

To discuss an infection that is not improving, review an antibiotic allergy label, or address diarrhoea after antibiotics, contact us or schedule a visit.